Mark S Shaefer
Overview
Explore the profile of Mark S Shaefer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
347
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mounzer K, Fusco J, Hsu R, Brunet L, Vannappagari V, Frost K, et al.
AIDS Patient Care STDS
. 2021 Oct;
35(11):419-427.
PMID: 34609897
Preventing HIV transmission is a crucial step in ending the HIV epidemic. Safe and effective pre-exposure prophylaxis (PrEP) has been available in the United States since 2012. We set out...
2.
Chounta V, Overton E, Mills A, Swindells S, Benn P, Vanveggel S, et al.
Patient
. 2021 May;
14(6):849-862.
PMID: 34056699
Background: Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, which share similar high efficacy rates. Consequently, more emphasis is being placed...
3.
Mounzer K, Brunet L, Wyatt C, Fusco J, Vannappagari V, Tenorio A, et al.
AIDS
. 2021 Mar;
35(8):1201-1208.
PMID: 33710017
Objectives: To assess the risk of adverse diagnoses and laboratory abnormalities associated with a 300 or 150 mg daily dose of lamivudine (3TC) initiated by people with HIV (PWH) with...
4.
Ross L, Walker A, Lou Y, Tenorio A, Gibb D, Double J, et al.
PLoS One
. 2019 Nov;
14(11):e0225199.
PMID: 31725787
A retrospective analysis of the randomized controlled DART (Development of AntiRetroviral Therapy in Africa; ISRCTN13968779) trial in HIV-1-positive adults initiating antiretroviral therapy with co-formulated zidovudine/lamivudine plus either tenofovir, abacavir, or...
5.
Mounzer K, Hsu R, Fusco J, Brunet L, Henegar C, Vannappagari V, et al.
AIDS Res Ther
. 2019 Jan;
16(1):1.
PMID: 30651100
Background: HLA-B*57:01 screening was added to clinical care guidelines in 2008 to reduce the risk of hypersensitivity reaction from abacavir. The uptake of HLA-B*57:01 screening and incidence of hypersensitivity reaction...
6.
Stainsby C, Perger T, Vannappagari V, Mounzer K, Hsu R, Henegar C, et al.
Pharmacotherapy
. 2018 Nov;
39(1):40-54.
PMID: 30414209
Introduction: Human leukocyte antigen (HLA)-B*5701 screening identifies patients at increased risk for abacavir (ABC) hypersensitivity reaction (HSR). Screening was adopted in GlaxoSmithKline and ViiV Healthcare clinical trials in 2007 and...
7.
Robertson K, Maruff P, Ross L, Wohl D, Small C, Edelstein H, et al.
J Neurovirol
. 2018 Oct;
25(1):22-31.
PMID: 30298202
Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate...
8.
Ross L, Shortino D, Shaefer M
AIDS Res Hum Retroviruses
. 2018 May;
34(8):672-679.
PMID: 29732898
Pre-existing HIV drug resistance can jeopardize first-line antiretroviral therapy (ART) success. Changes in the prevalence of drug resistance-associated mutations (DRMs) were analyzed from HIV-infected, ART-naive, U.S. individuals seeking ART treatment...
9.
Squires K, Young B, Santiago L, Dretler R, Walmsley S, Zhao H, et al.
HIV AIDS (Auckl)
. 2017 Apr;
9:51-61.
PMID: 28424561
Purpose: The 144-week results of the open-label, multicenter Atazanavir/Ritonavir Induction with Epzicom Study (ARIES) were stratified by gender to compare treatment responses. Methods: A total of 369 HIV-infected, antiretroviral-naïve subjects...
10.
Small C, Margolis D, Shaefer M, Ross L
BMC Infect Dis
. 2017 Apr;
17(1):256.
PMID: 28399804
Background: The presence of the HLA-B*57:01 allele in HIV-infected subjects is associated with a higher risk of abacavir-associated hypersensitivity reaction (ABC HSR). HLA-B*57:01 allele prevalence varies in different populations, but...